Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis has
Deep in a budget deal Congress passed earlier this year was a hit to pharmaceutical companies that will cost them billions, and could signal more losses to come
Pennsylvania has proposed legislation (PA HB 941) to reconfigure the payment rates used for Medicaid prescriptions paid by Medicaid MCOs to pharmacies. This study conveys findings from our efforts to reprice Pennsylvania’s 2018 Medicaid MCO prescription drug claims to estimate
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on legislation introduced by Senate Finance Committee members: The just-released Senate Finance Committee legislation enables Big Pharma to profit immensely from the high list prices big
Congress has shown it has both the appetite and ability to enact prescription drug pricing policy.
So now we need those of us in the private market to do our part.
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
Drug manufacturers have leveraged limited competition in the insulin market to increase the list price of insulin products over the past 10 years. PBMs, on the other hand, are working on behalf of patients to negotiate lower costs and increase access to these needed medications. PBMs have stepped up efforts to help patients living with diabetes afford their medications by introducing new programs to cap, or outright eliminate, out-of-pocket costs on insulin.
Greg Lopes, a spokesman for the Pharmaceutical Care Management Association, said PBMs believe the key to lowering costs for insulin, and drugs more broadly, is more competition among manufacturers. He said drug companies have avoided doing that through tactics like extending patents on insulin products.
“Frozen formulary” legislation refers to regulations proposed by state legislators that would prohibit a pharmacy benefit manager (PBM) or health plan from making certain changes to a prescription formulary midyear. Based on a recent analysis, Milliman estimates the proposed “frozen formulary”
©2024 PCMA. All Rights Reserved.
